News & Media

Patients being treated for schizophrenia now have a new administration site option for Abilify MaintenaApproval was based on data demonstrating pharmacokinetics, tolerability and safety of Abilify Maintena when injected in the deltoid muscle of the arm being comparable to gluteal administrationThe option for deltoid administration of Abilify Maintena provides patients and physicians more

There are approximately 15 million adults in the U.S. with major depressive disorder (MDD), and many of them have an inadequate response to monotherapy with antidepressants 1,2. There are 2.4 million adults with schizophrenia in the U.S., many of whom continue to need effective treatments.1The approval of REXULTI is based on a clinical program in which REXULTI showed improvement vs. placebo in

Tokyo, Japan and Deerfield, Ill. – May 12, 2015 – Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck today announced the presentation of several posters highlighting pre-clinical and clinical trial data for brexpiprazole, a novel investigational compound currently under review by the FDA as a potential monotherapy in adults with schizophrenia and as an adjunctive therapy in adults

Brexpiprazole demonstrated statistically significant efficacy vs. placebo in PANSS (Positive and Negative Syndrome Scale) Total Score in adult patients with schizophrenia.iBrexpiprazole is a serotonin-dopamine activity modulator (SDAM). Brexpiprazole is a partial agonist at 5-HT1Aand dopamine D2 receptors at relatively equal potency, an antagonist at 5-HT2A and an antagonist at noradrenaline